Accepted Manuscript Analyst

This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](http://www.rsc.org/Publishing/Journals/guidelines/AuthorGuidelines/JournalPolicy/accepted_manuscripts.asp).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](http://www.rsc.org/help/termsconditions.asp) and the Ethical quidelines still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

www.rsc.org/analyst

ARTICLE TYPE

Stimulated mass enhancement strategy-based highly sensitive detection of a protein in serum using quartz crystal microbalance technique†

Rashida Akter,Bongjin Jeong and Md. Aminur Rahman *

Received (in XXX, XXX) Xth XXXXXXXXX 20XX, Accepted Xth XXXXXXXXX 20XX ⁵**DOI: 10.1039/b000000x**

A stimulated mass enhancement strategy based on enormous biocatalytic precipitations of 4-chloro-1-naphthol (CN) using magnetic bead (MB)-supported horseradish peroxidase (HRP) and glucose oxidase (GOx) bienzymes was developed ¹⁰**for the highly sensitive detection of interleukin-6 (IL-6) in serum using quartz crystal microbalance (QCM) technique.**

The sensitive detection of protein biomarkers in real serum samples plays an important role for diagnosing diseases at an early state. Conventional immunoassay methods for proteins ¹⁵detection in serum include enzyme-linked immunosorbent assay $(ELISA)$, radioimmunoassay $(RIA)^2$ fluorescence.³ chemiluminescence,⁴ electrophoretic,⁵ and mass spectrometric immunoassays⁶ suffers from drawbacks: time-consuming, radiation hazards, tedious, expensive, need for skilled personnel, ²⁰and sophisticated instrumentation. As alternatives to the conventional immunoassay procedures, immunosensor methods based on surface plasma resonance (SPR) , chemiluminescence, 8 electrochemistry⁹ and quartz crystal microbalance (QCM) ,¹⁰ have been developed for the protein detection. Of these, the QCM ²⁵immunosensors have shown great promises as the real-time and label-free detection can be achieved with a high sensitivity and specificity. The QCM measure the decrease in resonant frequency, *f*0 (∆*f*), which linearly depends on the mass attached to the quartz crystal surface according to the Sauerbrey relationship;¹¹

 $\Delta f = -2 \Delta m n f_0^2 / [A(\mu_q \rho_q)^{1/2}]$ (1) where ∆*f* is the change in frequency (Hz), ∆*m* is the mass change (g), *n* is the overtone number, *A* is the area of the quartz crystal, μ_q is the shear modulus of the quartz (2.947 \times 10¹¹ g/(cm·sec²)), and ρ_q is the density of the quartz (2.648 g/cm³), assuming the ³⁵attached mass is rigid and strongly coupled to the resonator. The Sauerbrey equation does not apply for viscoelastic mass, therefore its analytical application is originally limited for the precise mass detection in liquid phase. However, it is reported that for a high frequency quartz $(\sim 10 \text{ MHz})$, the thickness of the ⁴⁰antibody/antigen monolayer is small compare to the acoustic wave length generated by the sensor.¹² Due to this very thin layer and the high frequency, the antibody/antigen behave like a glassy material, thus the viscoelastic effect is very small and can be neglected. Then, the Sauerbrey equation can be used for the mass 45 calculation. In this study, we were not aimed to precisely determine the surface coverage of protein from the frequency responses. Instead, we used the amplified frequency responses resulted from the enhanced mass changes for increasing the

sensitivity of a protein immunosensor. Previously, various ⁵⁰enzyme-based amplification strategies for the detection of enzyme, bacteria, and protein have been reported for increasing the sensitivity.¹³ However, in most cases, single enzyme was used as an enzymatic label and the sensitivities of these QCM immunosensors were not attractive, which need to be improved 55 for the practical application in serum samples.

 In the present study, we aimed to increase the QCM immunosensor's sensitivity by enhanced mass amplification strategy through the magnetic bead (MB)-stimulated bienzymatic precipitation of 4-chloro-1-naphthol (CN). For this, MBs ⁶⁰ (dynabeads[®]Myone™ Carboxylic acid, 1 μm diameter, Invitrogen) were used as nanocarriers for attaching numerous, HRP and GOx bienzymes with the secondary antibody (polyclonal interleukin-6 (anti-IL-6, $Ab₂$) produced in rabbit) (Fig. 1b). We chose MBs as they have high density of COOH groups 65 for covalently attaching numerous bienzymes and Ab₂. Also, MB provides simple and easy separation and purification of the bienzymes-Ab₂ conjugate by magnetic separation. In the presence of glucose and CN, the conjugates generate enormous amounts of benzo-4-chlorocyclohexadienone precipitates that accumulate on ⁷⁰the QCM surface resulting in an enhanced mass amplification. The resulting mass enhancement can be detected by monitoring the frequency change, where the magnitude of the frequency change corresponds to the concentration of protein bound to the immunosensor probe. No previous report using magnetic bead-⁷⁵bienzymatic bioconjugates in QCM have attempted for the detection of a protein biomarker through the biocatalytic precipitations. This enhanced mass amplification strategy has been used for the detection of a model multifunctional serum cytokine protein, interleukin-6 (IL-6), which is a biomarker for ⁸⁰several types of cancers including head and neck squamous cell carcinoma (HNSCC).¹⁴ The physiological level of IL-6 in healthy individuals is ≤ 6 pg ml⁻¹, whereas its level is over expressed in patient with HNSCC (≥ 20 pg ml⁻¹).¹⁵

 Fig. 1 outlines the design of a QCM immunosensor (see ESI† ⁸⁵for details) and the principle of the IL-6 detection. Briefly, a gold- coated QCM electrode (8 MHz AT-cut, QCM) was covered with a self-assembled monolayer (SAM) of 3-mercaptopropionic acid (MPA). The uncoated QCM sites were treated with mercaptoethanol. Protein A (PA) was then covalently attached on 90 the MPA-coated QCM electrode through the EDC/NHS coupling reaction, which forms amide bonds between the –COOH and – NH² groups of MPA and PA, respectively. Primary monoclonal

Fig. 1 Schematic illustration of the (a) fabrication of QCM immunesen-¹⁵sor, (b) preparation of the bioconjugate, and (c) IL-6 detection principle.

anti-IL-6 antibody $(Ab₁)$ was then immobilized onto the QCM/MPA/PA through the selective interaction between PA and the Fc region of $Ab₁$ antibody with controlled orientation (Fig. 1a). After washing and blocking the immunosensor surface using $20\,1\%$ bovine serum albumin (BSA), the QCM/MPA/PA/Ab₁ surface was treated with various concentrations of IL-6 protein in serum. The immunosensor probe was finally fabricated by immunointeracting the Ab₂/MB/HRP/GOx bioconjugate with the QCM/MPA/PA/Ab₁/IL-6 probe. The final 25 QCM/MPA/PA/Ab₁/IL-6/Ab₂/MB/HRP/GOx (Fig. 1c) probe was assembled into a QCM cell and was connected to an oscillator. Then, the bienzymatic precipitation of CN was followed by introducing an optimum concentration CN and β-glucose in PBS. Frequency responses were continuously measured unless a steady ³⁰state level was reached. The IL-6 detection was based on the multiple HRP particles induces conversion of CN to benzo-4 chlorocyclohexadienone precipitates in the presence of *in situ* generated H_2O_2 by GOx and glucose, which accumulated on the QCM crystal surface resulted in a dramatic amplification in 35 frequency responses due to the enhanced mass amplification.

The Ab₂/MB/HRP/GOx bioconjugate was characterized using scanning electron microscopy (SEM) technique. Fig. 2a and 2b show the SEM images obtained for a MB and anti-Ab² /MB/HRP/GOx conjugate**,** respectively. The SEM image of ⁴⁰the conjugate clearly shows there are over layers covered the surface of the MB and the brightness of the bare MB surface decreased upon conjugation. The diameter of the MB increased after the Ab₂/HRP/GOx conjugation, which are uniformly distributed and separated from each other. The increased diameter ⁴⁵of the conjugate was further confirmed using the dynamic light scattering (DLS) technique. The hydrodynamic diameter of the conjugate (1250 nm) was found to be increased than that of a bare MB (1119 nm) (Fig. S1, ESI†), clearly proved the formation

Fig. 2 SEM images of (a) MB and (b) Ab₂/MB/HRP/GOx conjugates. Insets show the images of bare MB and conjugate.

Fig. 3 (a) CVs and (b) Nyquist plots of the EIS spectra for the (i) bare 60 QCM, (ii) QCM/MPA, (iii) QCM/MPA/PA and (iv) QCM/MPA/PA/anti-IL-6 modified electrodes in a 1.0 mM Fe(CN) $_6^{3-/4}$ solution. Insets show the Nyquist plot of the bare QCM electrode and the equivalent circuit.

of the MB-supported bioconjugate.

The cyclic voltammetry (CV) technique was performed for the ⁶⁵characterization of the immunosensor probe at different modification stages. Fig. 3a shows the CVs recorded for various modified electrodes in a $\text{Fe(CN)}_6^{3-/4}$ -solution. The CV for a (i) bare QCM electrode exhibited a peak separation (Δ*E*_p) value of about 0.07 V, indicating a quasi-reversible electron transfer ⁷⁰ process of Fe(CN)₆^{3.44} redox couple. However, the Δ*E*_p values for (ii) QCM/MPA $(0.11V)$, (iii) QCM/MPA/PA $(0.13V)$ and (iv) $QCM/MPA/PA/Ab₁$ (0.16V) modified electrodes showed irreversible processes of $\text{Fe(CN)}_6^{3-/4-}$ electron transfer. Additionally, the peak currents (I_p) of the Fe(CN)₆^{3-/4-} electron ⁷⁵transfer process significantly decreased as the MPA, PA, and $Ab₁$ were immobilized on the bare QCM electrode. The increased ΔE_p and decreased I_p values of Fe(CN)₆^{3-/4-} redox reaction for QCM/MPA , $QCM/MPA/PA$, and $QCM/MPA/PA/Ab$ ₁ modified electrodes indicate that the MPA, PA, and $Ab₁$ successfully ⁸⁰immobilized on the QCM electrode, which acted as barriers for the electron transfer process of $\text{Fe(CN)}_6^{3-/4-}$ couple. Electrochemical impedance spectroscopy (EIS)¹⁶ technique provides the information on the surface conductivity and could be used for the characterization of the immunosensor probe at 85 various modification steps in terms of charge transfer resistance (R_{ct}) . The R_{ct} value, which exhibits the charge transfer kinetics of the Fe(CN)_6^{3-4} redox system could be used to prove the existence of biomolecular layers on the modified electrode. Fig. 3b shows the Nyquist plots of EIS measurements for the bare (i) QCM, (ii) ⁹⁰ QCM/MPA, (iii) QCM/MPA/PA, and (iv) QCM/MPA/PA/Ab₁ modified electrodes recorded in a 1.0 mM $Fe(CN)_6^{3-44}$ solution. The R_{ct} values were determined from the diameters of the semicircle parts at higher frequencies in the Nyquist plots. The R_{ct} value of a bare QCM crystal (0.2 kΩ) increased to a value of $~6$ ⁹⁵kΩ, after the attachment of MPA (QCM/MPA), indicating that the MPA was covered on the QCM surface. The further increases in $R_{\rm ct}$ values for QCM/MPA/PA (~15 kΩ) and QCM/MPA/PA/Ab₁ (~24 kΩ) electrodes clearly revealed the successful immobilizations of PA and $Ab₁$ on the immunosensor probe.

100 For achieving the highest sensitivity, two control experiments were performed. Firstly, the non-specific adsorption of the conjugates and the non-specific binding of other biomolecules were examined by measuring the frequency responses during precipitation reaction with the immunosensor probe with or 105 without BSA blocking in PBS and serum samples (Fig. S2, ESI†). The results clearly show that the BSA blocking significantly minimized the non-specific adsorption of the conjugates or nonspecific binding of other biomolecules in serum samples.

Fig. 4 (a) Frequency responses measured during the precipitation 10 reaction with various concentrations of IL-6 in human serum: (i) 1, (ii) 2, (iii) 5, (iv) 10, (v) 15, (vi) 20, (vii) 30, (viii) 40, (ix) 50, (x) 60, and (xi) 70 pg/mL. Inset shows the responses at two lowest concentrations. (b) Corresponding calibration plot.

- 15 Secondly, the frequency response obtained with the anti-Ab² /MB/HRP/GOx conjugates was compared with that obtained for only Ab₂/HRP/GOx conjugates without magnetic bead (MB) (Fig.S3, ESI†). In the case of Ab² /HRP/GOx conjugates, the ∆*f* response did not significantly decreased (~5 Hz) due to the ²⁰formation of a less amount of precipitates by the lower amounts of bienzymes in the conjugates. The use of MB increases the
- amounts of HRP and GOx enzymes in the conjugates, thus enhanced the amount of precipitates formed resulted in a large decrease in ∆*f* response (~31 Hz). Thus, the highly sensitive ²⁵detection of IL-6 through the proposed enhanced mass
- amplification strategy was evaluated by measuring the ∆*f* response at various spiked IL-6 concentrations in human serum samples (Fig. 4a). As the concentration of IL-6 increased, the ∆*f* responses decreased due to the formation of more precipitates by
- 30 the larger amount of Ab₂/MB/HRP/GOx bioconjugates. The linear calibration plot of ∆*f* vs. IL-6 concentrations is shown in Fig. 4b. For a comparison, the calibration plot obtained in PBS is also shown. The ∆*f* responses in human serum samples were about 5% lower than that obtained in PBS. The lower responses
- ³⁵obtained were due to the presence of various matrices in serum samples. A linear dynamic range between 1 and 50 pg mL^{-1} concentration of IL-6 was observed. The limit of detection (LOD) was estimated to be 0.6 ± 0.036 pg mL⁻¹ (n = 5) based on 3 standard deviation units larger than the blank signal. The ⁴⁰reproducibility expressed in terms of the relative standard deviation (RSD) was about 6.7% (n=5) at 5 pg mL⁻¹ of IL-6. The observed LOD of IL-6 is comparable to that of a highly sensitive
	- electrochemical immunosensor $(0.5 \text{ pgmL}^{-1})^{17a}$ and much lower than that of other IL-6 immunosensors.¹⁷*b*,*^c*
- 45 No interferences from the other proteins such as human serum albumin (HSA), prostate specific antigen (PSA), human carcinoembryonic antigen (CEA), human immunoglobulin (IgG), and human thrombin (TB) were observed as the non-specific binding of other proteins were minimized by BSA blocking (Fig.
- ⁵⁰S4, ESI†). The stability of the proposed high sensitive QCM IL-6 immunosensor was determined for two months by measuring the response once a time in every two days after regeneration of the sensor surface (see ESI† for regeneration step). For six weeks, the ∆*f* responses retained almost 90 % of its initial response (Fig. S5,
- ⁵⁵ESI†). These results demonstrated that the proposed enhanced mass amplification strategy based QCM immunosensor hold great promise for IL-6 detection in serum samples with high specificity and stability.

In conclusion, we developed a stimulated mass enhancement ⁶⁰amplification strategy based on MB-supported bienzymatic precipitation for a high sensitive detection of IL-6 in serum. The IL-6 detection was based on the measurements of the enhanced decrement of the ∆*f* responses due to the accumulation of enormous amount of precipitates resulted from the biocatalytic 65 precipitation of CN by HRP and GOx in the conjugates. The proposed QCM immunosensor method could be used as a viable technique for the detection of other proteins in serum by simply changing the specific antibody in bioconjugates and in the immunosensor probe.

This research was supported by the Basic Research Program for regional university (2012R1A1A4A01007256) funded by the National Research Foundation, Korean government (MEST) and a Chungnam National University research grant (2014-0693-01).

⁷⁵*Graduate School of Analytical Science and Technology, Chungnam National University, Daejeon 305-764, South Korea Fax: 82-42-821-8541;Tel: 82-42-821-8546;E-mail:marahman@cnu.ac.kr* † Electronic supplementary information (ESI) available: Experimental details, Figs. S1, S2, S3, S4 and S5. See DOI: 10.1039/b000000x/

⁸⁰**Notes and references**

- 1 A. M. Yates, S. J. Elvin and D. E. Williamson, *J. Immunoassay*, 1999, *20*, 31-44.
- 2. M. Teppo and C. P. Maury, *J. Clin. Chem*., 1987, *33*, 2024-2027.
- 3 T. Li, E.-J. Jo and M.-G. Kim, *Chem. Commun*., 2012, *48*, 2304-2306.
- ⁸⁵4 Z. F. Fu, F. Yan, H. Liu, Z. J. Yang and H. X. Ju, *Biosens. Bioelectron.*, 2008, *23*, 1063-1069.
- 5 D. S. Reichmuth, S. K. Wang, L. M. Barrett, D. J. Throckmorton, W. Einfeld and A. K. Singh, *Lab Chip*, 2008, *8*, 1319-1324.
- 6 S. H. Hu, S. C. Zhang, Z. C. Hu, Z. Xing and X. R. Zhang, *Anal.* ⁹⁰*Chem.*, 2007, *79*, 923-929.
- 7 (*a*) C. Liu, T. Lei, K. Ino. T. Matsue, N. Tao and C.-Z. Li, *Chem. Commun*., 2012, *48*, 10389-10391; (*b*) S. Krishnan, V. Mani, D. Wasalathanthri, C. V. Kumar and J. F. Rusling, *Angew Chem. Int. Ed*. 2011, *50*, 1175-1178.
- ⁹⁵8 (*a*) G.-F. Jie, P. Liu and S.-S. Zhang, *Chem. Commun*., 2010, *46*, 1323-1325; (*b*) G. Jie, L. Li, C. Chen, J.Xuan and J. Zhu, *Biosens. Bioelectron.*, 2010, *25*, 1781-1788.
- 9 (*a*) B. S. Munge, A. L. Coffey, J. M. Doucette, B. K. Somba, R. Malhotra, V. Patel, J. S. Gutkind and J. F. Rusling, *Angew Chem. Int.* ¹⁰⁰*Ed*. 2011, *50*, 7915-7918; (*b*) K. Chuah, L. M. H. Lai, I. Y. Goon, S.
- G. Parker and J. J. Gooding, *Chem. Commun*., 2012, *48*, 3503-3505. 10 (*a*) D. Tang, R. Yuan, Y. Chai, *Analyst*, 2008, *133*, 933-938; (*b*) S. M.
- Knudsen, J. Lee, A. D. Ellington, and C. A. Savran, *J. Am. Chem. Soc*., 2006, *128*, 15936-15937.
- ¹⁰⁵11 G. Sauerbrey, *Z. Phys*. 1959, *155*, 206-222.
	- 12 S. P. Sakti, P. Hauptmann, B. Zimmermann, F. Buhling and S. Ansorge, *Sens. Actuators, B*, 2001, *78*, 257-262.
- 13 (*a*) R. C. Ebersole and M. D. Ward, *J. Am. Chem. Soc*., 1988, *110*, 6494-6498; (*b*) C. Ruan, K. Zeng, O. K. Varghese and C. A. Grimes, ¹¹⁰*Anal. Chem*., 2003, *75*, 6494-6498; (*c*) J. Zhou, N. Gan, T. Li, H. Zhou, X. Li, Y. Cao, L. Wang, W. Sang and F. Hu, *Sens. Actuators, B*, 2013, *178*, 494-500.
	- 14 T. Kishimoto, *Annu. Rev. Immunol*. 2005, *23*, 1-21.
- 15 D. S. Hong, L. S. Angelo, and R. Kurzrock, *Cancer* 2007, *110*, 1911- 115 1928.
- 16 A. J. Bard and L. R. Faulkner, *Electrochemical Methods: Fundamentals and Applications*, John Wiley & Sons Inc., New York, 2nd edn., 2001.
- 17 (*a*) R. Malhotra, V. Patel, J. P. Vaque, J. S. Gutkind and J. F. Rusling, ¹²⁰Anal. Chem. 2010, *82*, 3118-3123; (*b*) B. V. Chikkaveeraiah, A. Bhirde, R. Malhotra, V. Patel, J. S. Gutkind and J. F. Rusling, Anal. Chem. 2009, 81, 9129-9134; (*c*) B. S. Munge, C. E. Crause, R. Malhotra, V. Patel, J. S. Gutkind and J. F. Rusling, Electrochem. Commun. 2009, 11, 1009-1012.

Table of Contents

Stimulated mass enhancement strategy-based highly sensitive detection of a protein in serum using quartz crystal microbalance technique†

Rashida Akter, Bongjin Jeong and Md. Aminur Rahman *

Quartz crystal microbalance immunosenor for highly sensitive detection of interleukin-6 in serum using magnetic bead-supported-byenzymes catalyzed stimulated mass enhancement strategy.